nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—breast cancer	0.348	1	CbGaD
Rasagiline—BCL2—Paclitaxel—breast cancer	0.183	0.477	CbGbCtD
Rasagiline—BCL2—Docetaxel—breast cancer	0.132	0.345	CbGbCtD
Rasagiline—CYP1A2—Anastrozole—breast cancer	0.0275	0.0717	CbGbCtD
Rasagiline—CYP1A2—Toremifene—breast cancer	0.0252	0.0656	CbGbCtD
Rasagiline—CYP1A2—Tamoxifen—breast cancer	0.0092	0.0239	CbGbCtD
Rasagiline—CYP1A2—Fluorouracil—breast cancer	0.00678	0.0176	CbGbCtD
Rasagiline—BCL2—epithelium—breast cancer	0.0016	0.0882	CbGeAlD
Rasagiline—BCL2—skin of body—breast cancer	0.00152	0.0839	CbGeAlD
Rasagiline—BCL2—Tamoxifen—Toremifene—breast cancer	0.00148	1	CbGdCrCtD
Rasagiline—BCL2—endometrium—breast cancer	0.00143	0.0791	CbGeAlD
Rasagiline—BCL2—uterus—breast cancer	0.00132	0.0729	CbGeAlD
Rasagiline—BCL2—female reproductive system—breast cancer	0.00119	0.0655	CbGeAlD
Rasagiline—BCL2—bone marrow—breast cancer	0.00112	0.0618	CbGeAlD
Rasagiline—BCL2—female gonad—breast cancer	0.00108	0.0596	CbGeAlD
Rasagiline—BCL2—endocrine gland—breast cancer	0.001	0.0554	CbGeAlD
Rasagiline—MAOB—nipple—breast cancer	0.000989	0.0545	CbGeAlD
Rasagiline—MAOB—embryo—breast cancer	0.000816	0.045	CbGeAlD
Rasagiline—CYP1A2—nipple—breast cancer	0.000704	0.0388	CbGeAlD
Rasagiline—BCL2—lymph node—breast cancer	0.000695	0.0383	CbGeAlD
Rasagiline—MAOB—endometrium—breast cancer	0.000597	0.0329	CbGeAlD
Rasagiline—MAOB—uterus—breast cancer	0.00055	0.0303	CbGeAlD
Rasagiline—MAOB—pituitary gland—breast cancer	0.00054	0.0298	CbGeAlD
Rasagiline—MAOB—adipose tissue—breast cancer	0.000538	0.0297	CbGeAlD
Rasagiline—MAOB—female reproductive system—breast cancer	0.000494	0.0273	CbGeAlD
Rasagiline—MAOB—adrenal gland—breast cancer	0.000483	0.0266	CbGeAlD
Rasagiline—MAOB—female gonad—breast cancer	0.00045	0.0248	CbGeAlD
Rasagiline—MAOB—endocrine gland—breast cancer	0.000418	0.0231	CbGeAlD
Rasagiline—CYP1A2—endocrine gland—breast cancer	0.000298	0.0164	CbGeAlD
Rasagiline—MAOB—lymph node—breast cancer	0.000289	0.016	CbGeAlD
Rasagiline—Musculoskeletal discomfort—Docetaxel—breast cancer	2.07e-05	0.000136	CcSEcCtD
Rasagiline—Chills—Methotrexate—breast cancer	2.07e-05	0.000136	CcSEcCtD
Rasagiline—Headache—Irinotecan—breast cancer	2.06e-05	0.000135	CcSEcCtD
Rasagiline—Headache—Mitoxantrone—breast cancer	2.06e-05	0.000135	CcSEcCtD
Rasagiline—Hypotension—Capecitabine—breast cancer	2.05e-05	0.000135	CcSEcCtD
Rasagiline—Insomnia—Docetaxel—breast cancer	2.05e-05	0.000135	CcSEcCtD
Rasagiline—Paraesthesia—Docetaxel—breast cancer	2.04e-05	0.000134	CcSEcCtD
Rasagiline—Alopecia—Methotrexate—breast cancer	2.03e-05	0.000134	CcSEcCtD
Rasagiline—Vomiting—Gemcitabine—breast cancer	2.03e-05	0.000134	CcSEcCtD
Rasagiline—Dyspnoea—Docetaxel—breast cancer	2.02e-05	0.000133	CcSEcCtD
Rasagiline—Somnolence—Docetaxel—breast cancer	2.02e-05	0.000133	CcSEcCtD
Rasagiline—Mental disorder—Methotrexate—breast cancer	2.02e-05	0.000132	CcSEcCtD
Rasagiline—Rash—Gemcitabine—breast cancer	2.02e-05	0.000132	CcSEcCtD
Rasagiline—Dermatitis—Gemcitabine—breast cancer	2.01e-05	0.000132	CcSEcCtD
Rasagiline—Eye disorder—Epirubicin—breast cancer	2.01e-05	0.000132	CcSEcCtD
Rasagiline—Malnutrition—Methotrexate—breast cancer	2e-05	0.000132	CcSEcCtD
Rasagiline—Haemoglobin—Doxorubicin—breast cancer	2e-05	0.000132	CcSEcCtD
Rasagiline—Headache—Gemcitabine—breast cancer	2e-05	0.000132	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Capecitabine—breast cancer	2e-05	0.000132	CcSEcCtD
Rasagiline—Cardiac disorder—Epirubicin—breast cancer	2e-05	0.000131	CcSEcCtD
Rasagiline—Vomiting—Fluorouracil—breast cancer	2e-05	0.000131	CcSEcCtD
Rasagiline—Rhinitis—Doxorubicin—breast cancer	2e-05	0.000131	CcSEcCtD
Rasagiline—Dyspepsia—Docetaxel—breast cancer	2e-05	0.000131	CcSEcCtD
Rasagiline—Haemorrhage—Doxorubicin—breast cancer	1.99e-05	0.000131	CcSEcCtD
Rasagiline—Insomnia—Capecitabine—breast cancer	1.99e-05	0.000131	CcSEcCtD
Rasagiline—Hypoaesthesia—Doxorubicin—breast cancer	1.98e-05	0.00013	CcSEcCtD
Rasagiline—Rash—Fluorouracil—breast cancer	1.98e-05	0.00013	CcSEcCtD
Rasagiline—Dermatitis—Fluorouracil—breast cancer	1.98e-05	0.00013	CcSEcCtD
Rasagiline—Paraesthesia—Capecitabine—breast cancer	1.97e-05	0.00013	CcSEcCtD
Rasagiline—Decreased appetite—Docetaxel—breast cancer	1.97e-05	0.00013	CcSEcCtD
Rasagiline—Hypersensitivity—Paclitaxel—breast cancer	1.97e-05	0.00013	CcSEcCtD
Rasagiline—Headache—Fluorouracil—breast cancer	1.97e-05	0.000129	CcSEcCtD
Rasagiline—Urinary tract disorder—Doxorubicin—breast cancer	1.97e-05	0.000129	CcSEcCtD
Rasagiline—Oedema peripheral—Doxorubicin—breast cancer	1.96e-05	0.000129	CcSEcCtD
Rasagiline—Dysgeusia—Methotrexate—breast cancer	1.96e-05	0.000129	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Docetaxel—breast cancer	1.96e-05	0.000129	CcSEcCtD
Rasagiline—Connective tissue disorder—Doxorubicin—breast cancer	1.96e-05	0.000129	CcSEcCtD
Rasagiline—Dyspnoea—Capecitabine—breast cancer	1.96e-05	0.000129	CcSEcCtD
Rasagiline—Angiopathy—Epirubicin—breast cancer	1.95e-05	0.000128	CcSEcCtD
Rasagiline—Urethral disorder—Doxorubicin—breast cancer	1.95e-05	0.000128	CcSEcCtD
Rasagiline—Nausea—Mitoxantrone—breast cancer	1.95e-05	0.000128	CcSEcCtD
Rasagiline—Nausea—Irinotecan—breast cancer	1.95e-05	0.000128	CcSEcCtD
Rasagiline—Immune system disorder—Epirubicin—breast cancer	1.95e-05	0.000128	CcSEcCtD
Rasagiline—Mediastinal disorder—Epirubicin—breast cancer	1.94e-05	0.000128	CcSEcCtD
Rasagiline—Constipation—Docetaxel—breast cancer	1.94e-05	0.000127	CcSEcCtD
Rasagiline—Back pain—Methotrexate—breast cancer	1.94e-05	0.000127	CcSEcCtD
Rasagiline—Dyspepsia—Capecitabine—breast cancer	1.93e-05	0.000127	CcSEcCtD
Rasagiline—Chills—Epirubicin—breast cancer	1.93e-05	0.000127	CcSEcCtD
Rasagiline—Asthenia—Paclitaxel—breast cancer	1.92e-05	0.000126	CcSEcCtD
Rasagiline—Decreased appetite—Capecitabine—breast cancer	1.91e-05	0.000125	CcSEcCtD
Rasagiline—Alopecia—Epirubicin—breast cancer	1.9e-05	0.000125	CcSEcCtD
Rasagiline—Nausea—Gemcitabine—breast cancer	1.9e-05	0.000125	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Capecitabine—breast cancer	1.9e-05	0.000125	CcSEcCtD
Rasagiline—Pruritus—Paclitaxel—breast cancer	1.89e-05	0.000124	CcSEcCtD
Rasagiline—Mental disorder—Epirubicin—breast cancer	1.89e-05	0.000124	CcSEcCtD
Rasagiline—Constipation—Capecitabine—breast cancer	1.88e-05	0.000123	CcSEcCtD
Rasagiline—Malnutrition—Epirubicin—breast cancer	1.88e-05	0.000123	CcSEcCtD
Rasagiline—Feeling abnormal—Docetaxel—breast cancer	1.87e-05	0.000123	CcSEcCtD
Rasagiline—Nausea—Fluorouracil—breast cancer	1.87e-05	0.000123	CcSEcCtD
Rasagiline—Eye disorder—Doxorubicin—breast cancer	1.86e-05	0.000122	CcSEcCtD
Rasagiline—Ill-defined disorder—Methotrexate—breast cancer	1.86e-05	0.000122	CcSEcCtD
Rasagiline—Gastrointestinal pain—Docetaxel—breast cancer	1.86e-05	0.000122	CcSEcCtD
Rasagiline—Anaemia—Methotrexate—breast cancer	1.85e-05	0.000122	CcSEcCtD
Rasagiline—Cardiac disorder—Doxorubicin—breast cancer	1.85e-05	0.000122	CcSEcCtD
Rasagiline—Flatulence—Epirubicin—breast cancer	1.85e-05	0.000121	CcSEcCtD
Rasagiline—Dysgeusia—Epirubicin—breast cancer	1.84e-05	0.000121	CcSEcCtD
Rasagiline—Diarrhoea—Paclitaxel—breast cancer	1.83e-05	0.00012	CcSEcCtD
Rasagiline—Back pain—Epirubicin—breast cancer	1.81e-05	0.000119	CcSEcCtD
Rasagiline—Feeling abnormal—Capecitabine—breast cancer	1.81e-05	0.000119	CcSEcCtD
Rasagiline—Angiopathy—Doxorubicin—breast cancer	1.81e-05	0.000119	CcSEcCtD
Rasagiline—Malaise—Methotrexate—breast cancer	1.81e-05	0.000119	CcSEcCtD
Rasagiline—Muscle spasms—Epirubicin—breast cancer	1.8e-05	0.000118	CcSEcCtD
Rasagiline—Immune system disorder—Doxorubicin—breast cancer	1.8e-05	0.000118	CcSEcCtD
Rasagiline—Vertigo—Methotrexate—breast cancer	1.8e-05	0.000118	CcSEcCtD
Rasagiline—Gastrointestinal pain—Capecitabine—breast cancer	1.8e-05	0.000118	CcSEcCtD
Rasagiline—Mediastinal disorder—Doxorubicin—breast cancer	1.8e-05	0.000118	CcSEcCtD
Rasagiline—Abdominal pain—Docetaxel—breast cancer	1.79e-05	0.000118	CcSEcCtD
Rasagiline—Body temperature increased—Docetaxel—breast cancer	1.79e-05	0.000118	CcSEcCtD
Rasagiline—Leukopenia—Methotrexate—breast cancer	1.79e-05	0.000118	CcSEcCtD
Rasagiline—Chills—Doxorubicin—breast cancer	1.79e-05	0.000118	CcSEcCtD
Rasagiline—Dizziness—Paclitaxel—breast cancer	1.77e-05	0.000116	CcSEcCtD
Rasagiline—Alopecia—Doxorubicin—breast cancer	1.76e-05	0.000116	CcSEcCtD
Rasagiline—Cough—Methotrexate—breast cancer	1.75e-05	0.000115	CcSEcCtD
Rasagiline—Mental disorder—Doxorubicin—breast cancer	1.75e-05	0.000115	CcSEcCtD
Rasagiline—Urticaria—Capecitabine—breast cancer	1.75e-05	0.000115	CcSEcCtD
Rasagiline—Ill-defined disorder—Epirubicin—breast cancer	1.74e-05	0.000114	CcSEcCtD
Rasagiline—Abdominal pain—Capecitabine—breast cancer	1.74e-05	0.000114	CcSEcCtD
Rasagiline—Body temperature increased—Capecitabine—breast cancer	1.74e-05	0.000114	CcSEcCtD
Rasagiline—Convulsion—Methotrexate—breast cancer	1.74e-05	0.000114	CcSEcCtD
Rasagiline—Malnutrition—Doxorubicin—breast cancer	1.73e-05	0.000114	CcSEcCtD
Rasagiline—Anaemia—Epirubicin—breast cancer	1.73e-05	0.000114	CcSEcCtD
Rasagiline—Agitation—Epirubicin—breast cancer	1.72e-05	0.000113	CcSEcCtD
Rasagiline—Flatulence—Doxorubicin—breast cancer	1.71e-05	0.000112	CcSEcCtD
Rasagiline—Arthralgia—Methotrexate—breast cancer	1.71e-05	0.000112	CcSEcCtD
Rasagiline—Chest pain—Methotrexate—breast cancer	1.71e-05	0.000112	CcSEcCtD
Rasagiline—Vomiting—Paclitaxel—breast cancer	1.7e-05	0.000112	CcSEcCtD
Rasagiline—Dysgeusia—Doxorubicin—breast cancer	1.7e-05	0.000112	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.69e-05	0.000111	CcSEcCtD
Rasagiline—Malaise—Epirubicin—breast cancer	1.69e-05	0.000111	CcSEcCtD
Rasagiline—Rash—Paclitaxel—breast cancer	1.69e-05	0.000111	CcSEcCtD
Rasagiline—Dermatitis—Paclitaxel—breast cancer	1.69e-05	0.000111	CcSEcCtD
Rasagiline—Discomfort—Methotrexate—breast cancer	1.69e-05	0.000111	CcSEcCtD
Rasagiline—Vertigo—Epirubicin—breast cancer	1.68e-05	0.000111	CcSEcCtD
Rasagiline—Syncope—Epirubicin—breast cancer	1.68e-05	0.00011	CcSEcCtD
Rasagiline—Leukopenia—Epirubicin—breast cancer	1.68e-05	0.00011	CcSEcCtD
Rasagiline—Back pain—Doxorubicin—breast cancer	1.68e-05	0.00011	CcSEcCtD
Rasagiline—Headache—Paclitaxel—breast cancer	1.68e-05	0.00011	CcSEcCtD
Rasagiline—Hypersensitivity—Docetaxel—breast cancer	1.67e-05	0.00011	CcSEcCtD
Rasagiline—Muscle spasms—Doxorubicin—breast cancer	1.67e-05	0.00011	CcSEcCtD
Rasagiline—Confusional state—Methotrexate—breast cancer	1.65e-05	0.000108	CcSEcCtD
Rasagiline—Loss of consciousness—Epirubicin—breast cancer	1.65e-05	0.000108	CcSEcCtD
Rasagiline—Cough—Epirubicin—breast cancer	1.64e-05	0.000108	CcSEcCtD
Rasagiline—Asthenia—Docetaxel—breast cancer	1.63e-05	0.000107	CcSEcCtD
Rasagiline—Convulsion—Epirubicin—breast cancer	1.62e-05	0.000107	CcSEcCtD
Rasagiline—Infection—Methotrexate—breast cancer	1.62e-05	0.000107	CcSEcCtD
Rasagiline—Hypertension—Epirubicin—breast cancer	1.62e-05	0.000106	CcSEcCtD
Rasagiline—Hypersensitivity—Capecitabine—breast cancer	1.62e-05	0.000106	CcSEcCtD
Rasagiline—Ill-defined disorder—Doxorubicin—breast cancer	1.61e-05	0.000106	CcSEcCtD
Rasagiline—Pruritus—Docetaxel—breast cancer	1.61e-05	0.000105	CcSEcCtD
Rasagiline—Nervous system disorder—Methotrexate—breast cancer	1.6e-05	0.000105	CcSEcCtD
Rasagiline—Anaemia—Doxorubicin—breast cancer	1.6e-05	0.000105	CcSEcCtD
Rasagiline—Arthralgia—Epirubicin—breast cancer	1.6e-05	0.000105	CcSEcCtD
Rasagiline—Chest pain—Epirubicin—breast cancer	1.6e-05	0.000105	CcSEcCtD
Rasagiline—Agitation—Doxorubicin—breast cancer	1.59e-05	0.000105	CcSEcCtD
Rasagiline—Anxiety—Epirubicin—breast cancer	1.59e-05	0.000105	CcSEcCtD
Rasagiline—Nausea—Paclitaxel—breast cancer	1.59e-05	0.000104	CcSEcCtD
Rasagiline—Skin disorder—Methotrexate—breast cancer	1.59e-05	0.000104	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.59e-05	0.000104	CcSEcCtD
Rasagiline—Hyperhidrosis—Methotrexate—breast cancer	1.58e-05	0.000104	CcSEcCtD
Rasagiline—Discomfort—Epirubicin—breast cancer	1.58e-05	0.000104	CcSEcCtD
Rasagiline—Asthenia—Capecitabine—breast cancer	1.58e-05	0.000104	CcSEcCtD
Rasagiline—Malaise—Doxorubicin—breast cancer	1.56e-05	0.000103	CcSEcCtD
Rasagiline—Dry mouth—Epirubicin—breast cancer	1.56e-05	0.000103	CcSEcCtD
Rasagiline—Vertigo—Doxorubicin—breast cancer	1.56e-05	0.000102	CcSEcCtD
Rasagiline—Anorexia—Methotrexate—breast cancer	1.56e-05	0.000102	CcSEcCtD
Rasagiline—Syncope—Doxorubicin—breast cancer	1.56e-05	0.000102	CcSEcCtD
Rasagiline—Pruritus—Capecitabine—breast cancer	1.55e-05	0.000102	CcSEcCtD
Rasagiline—Leukopenia—Doxorubicin—breast cancer	1.55e-05	0.000102	CcSEcCtD
Rasagiline—Diarrhoea—Docetaxel—breast cancer	1.55e-05	0.000102	CcSEcCtD
Rasagiline—Confusional state—Epirubicin—breast cancer	1.54e-05	0.000101	CcSEcCtD
Rasagiline—Hypotension—Methotrexate—breast cancer	1.53e-05	0.0001	CcSEcCtD
Rasagiline—Loss of consciousness—Doxorubicin—breast cancer	1.52e-05	0.0001	CcSEcCtD
Rasagiline—Infection—Epirubicin—breast cancer	1.52e-05	9.99e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—HSP90AA1—breast cancer	1.52e-05	0.000159	CbGpPWpGaD
Rasagiline—Cough—Doxorubicin—breast cancer	1.51e-05	9.95e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ESRRA—breast cancer	1.51e-05	0.000158	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ANGPTL4—breast cancer	1.51e-05	0.000158	CbGpPWpGaD
Rasagiline—Shock—Epirubicin—breast cancer	1.51e-05	9.89e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—FOS—breast cancer	1.5e-05	0.000157	CbGpPWpGaD
Rasagiline—Convulsion—Doxorubicin—breast cancer	1.5e-05	9.88e-05	CcSEcCtD
Rasagiline—Diarrhoea—Capecitabine—breast cancer	1.5e-05	9.88e-05	CcSEcCtD
Rasagiline—Nervous system disorder—Epirubicin—breast cancer	1.5e-05	9.86e-05	CcSEcCtD
Rasagiline—Dizziness—Docetaxel—breast cancer	1.5e-05	9.86e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—EGR1—breast cancer	1.5e-05	0.000157	CbGpPWpGaD
Rasagiline—Hypertension—Doxorubicin—breast cancer	1.5e-05	9.84e-05	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Methotrexate—breast cancer	1.49e-05	9.79e-05	CcSEcCtD
Rasagiline—Skin disorder—Epirubicin—breast cancer	1.49e-05	9.77e-05	CcSEcCtD
Rasagiline—Hyperhidrosis—Epirubicin—breast cancer	1.48e-05	9.72e-05	CcSEcCtD
Rasagiline—Insomnia—Methotrexate—breast cancer	1.48e-05	9.72e-05	CcSEcCtD
Rasagiline—Arthralgia—Doxorubicin—breast cancer	1.48e-05	9.71e-05	CcSEcCtD
Rasagiline—Chest pain—Doxorubicin—breast cancer	1.48e-05	9.71e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—PRL—breast cancer	1.48e-05	0.000154	CbGpPWpGaD
Rasagiline—Anxiety—Doxorubicin—breast cancer	1.47e-05	9.67e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CASP8—breast cancer	1.47e-05	0.000153	CbGpPWpGaD
Rasagiline—Paraesthesia—Methotrexate—breast cancer	1.47e-05	9.65e-05	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.47e-05	9.64e-05	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—AKT1—breast cancer	1.46e-05	0.000153	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP17A1—breast cancer	1.46e-05	0.000153	CbGpPWpGaD
Rasagiline—Discomfort—Doxorubicin—breast cancer	1.46e-05	9.59e-05	CcSEcCtD
Rasagiline—Anorexia—Epirubicin—breast cancer	1.46e-05	9.58e-05	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	1.46e-05	0.000152	CbGpPWpGaD
Rasagiline—Dyspnoea—Methotrexate—breast cancer	1.46e-05	9.58e-05	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—COMT—breast cancer	1.46e-05	0.000152	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—breast cancer	1.46e-05	0.000152	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—breast cancer	1.46e-05	0.000152	CbGpPWpGaD
Rasagiline—Somnolence—Methotrexate—breast cancer	1.45e-05	9.55e-05	CcSEcCtD
Rasagiline—Dizziness—Capecitabine—breast cancer	1.45e-05	9.54e-05	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTP1—breast cancer	1.45e-05	0.000151	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ENO1—breast cancer	1.45e-05	0.000151	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS1—breast cancer	1.45e-05	0.000151	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—breast cancer	1.45e-05	0.000151	CbGpPWpGaD
Rasagiline—Dry mouth—Doxorubicin—breast cancer	1.44e-05	9.49e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—AKT2—breast cancer	1.44e-05	0.000151	CbGpPWpGaD
Rasagiline—Vomiting—Docetaxel—breast cancer	1.44e-05	9.48e-05	CcSEcCtD
Rasagiline—Dyspepsia—Methotrexate—breast cancer	1.44e-05	9.46e-05	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—COMT—breast cancer	1.44e-05	0.00015	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—HADHB—breast cancer	1.43e-05	0.00015	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTP1—breast cancer	1.43e-05	0.000149	CbGpPWpGaD
Rasagiline—Rash—Docetaxel—breast cancer	1.43e-05	9.4e-05	CcSEcCtD
Rasagiline—Hypotension—Epirubicin—breast cancer	1.43e-05	9.4e-05	CcSEcCtD
Rasagiline—Dermatitis—Docetaxel—breast cancer	1.43e-05	9.39e-05	CcSEcCtD
Rasagiline—Confusional state—Doxorubicin—breast cancer	1.43e-05	9.38e-05	CcSEcCtD
Rasagiline—Decreased appetite—Methotrexate—breast cancer	1.42e-05	9.34e-05	CcSEcCtD
Rasagiline—Headache—Docetaxel—breast cancer	1.42e-05	9.34e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—CYP2D6—breast cancer	1.42e-05	0.000148	CbGpPWpGaD
Rasagiline—BCL2—Immune System—FGF10—breast cancer	1.42e-05	0.000148	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Methotrexate—breast cancer	1.41e-05	9.28e-05	CcSEcCtD
Rasagiline—Infection—Doxorubicin—breast cancer	1.41e-05	9.24e-05	CcSEcCtD
Rasagiline—Vomiting—Capecitabine—breast cancer	1.4e-05	9.18e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—NCOA2—breast cancer	1.39e-05	0.000146	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Epirubicin—breast cancer	1.39e-05	9.16e-05	CcSEcCtD
Rasagiline—Shock—Doxorubicin—breast cancer	1.39e-05	9.15e-05	CcSEcCtD
Rasagiline—Nervous system disorder—Doxorubicin—breast cancer	1.39e-05	9.12e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PIK3CD—breast cancer	1.39e-05	0.000145	CbGpPWpGaD
Rasagiline—Rash—Capecitabine—breast cancer	1.38e-05	9.1e-05	CcSEcCtD
Rasagiline—Insomnia—Epirubicin—breast cancer	1.38e-05	9.09e-05	CcSEcCtD
Rasagiline—Dermatitis—Capecitabine—breast cancer	1.38e-05	9.09e-05	CcSEcCtD
Rasagiline—Headache—Capecitabine—breast cancer	1.38e-05	9.04e-05	CcSEcCtD
Rasagiline—Skin disorder—Doxorubicin—breast cancer	1.38e-05	9.04e-05	CcSEcCtD
Rasagiline—Paraesthesia—Epirubicin—breast cancer	1.37e-05	9.03e-05	CcSEcCtD
Rasagiline—Hyperhidrosis—Doxorubicin—breast cancer	1.37e-05	8.99e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—PDGFA—breast cancer	1.37e-05	0.000143	CbGpPWpGaD
Rasagiline—Dyspnoea—Epirubicin—breast cancer	1.36e-05	8.96e-05	CcSEcCtD
Rasagiline—Somnolence—Epirubicin—breast cancer	1.36e-05	8.94e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—FASN—breast cancer	1.35e-05	0.000141	CbGpPWpGaD
Rasagiline—Anorexia—Doxorubicin—breast cancer	1.35e-05	8.87e-05	CcSEcCtD
Rasagiline—Nausea—Docetaxel—breast cancer	1.35e-05	8.86e-05	CcSEcCtD
Rasagiline—Feeling abnormal—Methotrexate—breast cancer	1.35e-05	8.85e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—BCHE—breast cancer	1.35e-05	0.000141	CbGpPWpGaD
Rasagiline—Dyspepsia—Epirubicin—breast cancer	1.35e-05	8.85e-05	CcSEcCtD
Rasagiline—Gastrointestinal pain—Methotrexate—breast cancer	1.34e-05	8.79e-05	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTM1—breast cancer	1.33e-05	0.000139	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SLC5A5—breast cancer	1.33e-05	0.000139	CbGpPWpGaD
Rasagiline—Decreased appetite—Epirubicin—breast cancer	1.33e-05	8.74e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—ITPR1—breast cancer	1.33e-05	0.000138	CbGpPWpGaD
Rasagiline—Hypotension—Doxorubicin—breast cancer	1.32e-05	8.69e-05	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Epirubicin—breast cancer	1.32e-05	8.68e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—STAT5A—breast cancer	1.32e-05	0.000137	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERBB4—breast cancer	1.32e-05	0.000137	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ABL1—breast cancer	1.32e-05	0.000137	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTM1—breast cancer	1.31e-05	0.000137	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—FHL2—breast cancer	1.31e-05	0.000137	CbGpPWpGaD
Rasagiline—Constipation—Epirubicin—breast cancer	1.31e-05	8.6e-05	CcSEcCtD
Rasagiline—Nausea—Capecitabine—breast cancer	1.3e-05	8.57e-05	CcSEcCtD
Rasagiline—Urticaria—Methotrexate—breast cancer	1.3e-05	8.54e-05	CcSEcCtD
Rasagiline—Body temperature increased—Methotrexate—breast cancer	1.29e-05	8.49e-05	CcSEcCtD
Rasagiline—Abdominal pain—Methotrexate—breast cancer	1.29e-05	8.49e-05	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.29e-05	8.48e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—SLC2A1—breast cancer	1.29e-05	0.000134	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NQO1—breast cancer	1.29e-05	0.000134	CbGpPWpGaD
Rasagiline—Insomnia—Doxorubicin—breast cancer	1.28e-05	8.42e-05	CcSEcCtD
Rasagiline—Paraesthesia—Doxorubicin—breast cancer	1.27e-05	8.35e-05	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—CYP1A1—breast cancer	1.26e-05	0.000132	CbGpPWpGaD
Rasagiline—Dyspnoea—Doxorubicin—breast cancer	1.26e-05	8.29e-05	CcSEcCtD
Rasagiline—Feeling abnormal—Epirubicin—breast cancer	1.26e-05	8.29e-05	CcSEcCtD
Rasagiline—Somnolence—Doxorubicin—breast cancer	1.26e-05	8.27e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—CYP3A4—breast cancer	1.25e-05	0.000131	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Epirubicin—breast cancer	1.25e-05	8.22e-05	CcSEcCtD
Rasagiline—Dyspepsia—Doxorubicin—breast cancer	1.25e-05	8.19e-05	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP1A1—breast cancer	1.25e-05	0.00013	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MDM2—breast cancer	1.24e-05	0.00013	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—RAF1—breast cancer	1.24e-05	0.000129	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HGF—breast cancer	1.24e-05	0.000129	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—RELA—breast cancer	1.23e-05	0.000129	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP1B1—breast cancer	1.23e-05	0.000129	CbGpPWpGaD
Rasagiline—Decreased appetite—Doxorubicin—breast cancer	1.23e-05	8.09e-05	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—breast cancer	1.23e-05	0.000128	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—ERBB2—breast cancer	1.23e-05	0.000128	CbGpPWpGaD
Rasagiline—BCL2—Immune System—FGF1—breast cancer	1.22e-05	0.000128	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD8A—breast cancer	1.22e-05	0.000128	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CSF2—breast cancer	1.22e-05	0.000128	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Doxorubicin—breast cancer	1.22e-05	8.03e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ABCC1—breast cancer	1.22e-05	0.000127	CbGpPWpGaD
Rasagiline—Urticaria—Epirubicin—breast cancer	1.22e-05	7.99e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—NRG1—breast cancer	1.21e-05	0.000127	CbGpPWpGaD
Rasagiline—Constipation—Doxorubicin—breast cancer	1.21e-05	7.96e-05	CcSEcCtD
Rasagiline—Abdominal pain—Epirubicin—breast cancer	1.21e-05	7.95e-05	CcSEcCtD
Rasagiline—Body temperature increased—Epirubicin—breast cancer	1.21e-05	7.95e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PIK3CB—breast cancer	1.21e-05	0.000126	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MTOR—breast cancer	1.21e-05	0.000126	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—HSP90AA1—breast cancer	1.21e-05	0.000126	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CD4—breast cancer	1.21e-05	0.000126	CbGpPWpGaD
Rasagiline—Hypersensitivity—Methotrexate—breast cancer	1.2e-05	7.92e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1B—breast cancer	1.18e-05	0.000123	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NCOA1—breast cancer	1.18e-05	0.000123	CbGpPWpGaD
Rasagiline—Asthenia—Methotrexate—breast cancer	1.17e-05	7.71e-05	CcSEcCtD
Rasagiline—Feeling abnormal—Doxorubicin—breast cancer	1.17e-05	7.67e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—STK11—breast cancer	1.16e-05	0.000121	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP19A1—breast cancer	1.16e-05	0.000121	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Doxorubicin—breast cancer	1.16e-05	7.61e-05	CcSEcCtD
Rasagiline—Pruritus—Methotrexate—breast cancer	1.16e-05	7.6e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—ERBB3—breast cancer	1.14e-05	0.000119	CbGpPWpGaD
Rasagiline—BCL2—Immune System—FGFR2—breast cancer	1.14e-05	0.000119	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CDKN1B—breast cancer	1.13e-05	0.000118	CbGpPWpGaD
Rasagiline—Hypersensitivity—Epirubicin—breast cancer	1.13e-05	7.41e-05	CcSEcCtD
Rasagiline—Urticaria—Doxorubicin—breast cancer	1.12e-05	7.39e-05	CcSEcCtD
Rasagiline—Abdominal pain—Doxorubicin—breast cancer	1.12e-05	7.35e-05	CcSEcCtD
Rasagiline—Body temperature increased—Doxorubicin—breast cancer	1.12e-05	7.35e-05	CcSEcCtD
Rasagiline—Diarrhoea—Methotrexate—breast cancer	1.12e-05	7.35e-05	CcSEcCtD
Rasagiline—Asthenia—Epirubicin—breast cancer	1.1e-05	7.21e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—GPX2—breast cancer	1.09e-05	0.000113	CbGpPWpGaD
Rasagiline—Pruritus—Epirubicin—breast cancer	1.08e-05	7.11e-05	CcSEcCtD
Rasagiline—Dizziness—Methotrexate—breast cancer	1.08e-05	7.11e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—JUN—breast cancer	1.08e-05	0.000113	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—COMT—breast cancer	1.08e-05	0.000112	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—breast cancer	1.07e-05	0.000112	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTP1—breast cancer	1.07e-05	0.000112	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CTNNB1—breast cancer	1.07e-05	0.000112	CbGpPWpGaD
Rasagiline—BCL2—Immune System—FGFR1—breast cancer	1.06e-05	0.000111	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—HMOX1—breast cancer	1.06e-05	0.00011	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ITPR1—breast cancer	1.05e-05	0.00011	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—breast cancer	1.05e-05	0.000109	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CDKN1A—breast cancer	1.05e-05	0.000109	CbGpPWpGaD
Rasagiline—BCL2—Immune System—BCL2L1—breast cancer	1.05e-05	0.000109	CbGpPWpGaD
Rasagiline—Diarrhoea—Epirubicin—breast cancer	1.05e-05	6.88e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PTEN—breast cancer	1.04e-05	0.000109	CbGpPWpGaD
Rasagiline—Hypersensitivity—Doxorubicin—breast cancer	1.04e-05	6.85e-05	CcSEcCtD
Rasagiline—Vomiting—Methotrexate—breast cancer	1.04e-05	6.83e-05	CcSEcCtD
Rasagiline—Rash—Methotrexate—breast cancer	1.03e-05	6.77e-05	CcSEcCtD
Rasagiline—Dermatitis—Methotrexate—breast cancer	1.03e-05	6.77e-05	CcSEcCtD
Rasagiline—Headache—Methotrexate—breast cancer	1.02e-05	6.73e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—MAPK8—breast cancer	1.02e-05	0.000107	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SYNJ2—breast cancer	1.02e-05	0.000106	CbGpPWpGaD
Rasagiline—Asthenia—Doxorubicin—breast cancer	1.02e-05	6.68e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—ABCB1—breast cancer	1.01e-05	0.000106	CbGpPWpGaD
Rasagiline—Dizziness—Epirubicin—breast cancer	1.01e-05	6.65e-05	CcSEcCtD
Rasagiline—Pruritus—Doxorubicin—breast cancer	1e-05	6.58e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—TYMS—breast cancer	9.97e-06	0.000104	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTM1—breast cancer	9.85e-06	0.000103	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PLA2G4A—breast cancer	9.85e-06	0.000103	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NCOR1—breast cancer	9.85e-06	0.000103	CbGpPWpGaD
Rasagiline—Vomiting—Epirubicin—breast cancer	9.73e-06	6.39e-05	CcSEcCtD
Rasagiline—Nausea—Methotrexate—breast cancer	9.71e-06	6.38e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—SRC—breast cancer	9.69e-06	0.000101	CbGpPWpGaD
Rasagiline—Diarrhoea—Doxorubicin—breast cancer	9.69e-06	6.37e-05	CcSEcCtD
Rasagiline—Rash—Epirubicin—breast cancer	9.65e-06	6.34e-05	CcSEcCtD
Rasagiline—Dermatitis—Epirubicin—breast cancer	9.64e-06	6.33e-05	CcSEcCtD
Rasagiline—Headache—Epirubicin—breast cancer	9.59e-06	6.3e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—NFKBIA—breast cancer	9.49e-06	9.91e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NDUFS3—breast cancer	9.45e-06	9.87e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GPX1—breast cancer	9.43e-06	9.85e-05	CbGpPWpGaD
Rasagiline—Dizziness—Doxorubicin—breast cancer	9.36e-06	6.15e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—CYP1A1—breast cancer	9.34e-06	9.75e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ERCC2—breast cancer	9.26e-06	9.67e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KIT—breast cancer	9.19e-06	9.6e-05	CbGpPWpGaD
Rasagiline—Nausea—Epirubicin—breast cancer	9.09e-06	5.97e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—MED12—breast cancer	9.09e-06	9.49e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGF—breast cancer	9.08e-06	9.48e-05	CbGpPWpGaD
Rasagiline—Vomiting—Doxorubicin—breast cancer	9e-06	5.92e-05	CcSEcCtD
Rasagiline—Rash—Doxorubicin—breast cancer	8.93e-06	5.87e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—MAPK3—breast cancer	8.93e-06	9.32e-05	CbGpPWpGaD
Rasagiline—Dermatitis—Doxorubicin—breast cancer	8.92e-06	5.86e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—CHST9—breast cancer	8.89e-06	9.28e-05	CbGpPWpGaD
Rasagiline—Headache—Doxorubicin—breast cancer	8.87e-06	5.83e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—FOS—breast cancer	8.76e-06	9.15e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—MTHFR—breast cancer	8.71e-06	9.09e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOA3—breast cancer	8.69e-06	9.07e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CASP8—breast cancer	8.56e-06	8.94e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EGFR—breast cancer	8.49e-06	8.87e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDH1—breast cancer	8.46e-06	8.83e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CPT1A—breast cancer	8.45e-06	8.82e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—COX11—breast cancer	8.42e-06	8.8e-05	CbGpPWpGaD
Rasagiline—Nausea—Doxorubicin—breast cancer	8.41e-06	5.53e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—AKT2—breast cancer	8.41e-06	8.78e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—breast cancer	8.29e-06	8.65e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CD—breast cancer	8.08e-06	8.44e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—breast cancer	8.04e-06	8.39e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CAV1—breast cancer	8.03e-06	8.38e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KRAS—breast cancer	8.02e-06	8.38e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CDA—breast cancer	7.7e-06	8.04e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SHMT1—breast cancer	7.7e-06	8.04e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—breast cancer	7.61e-06	7.94e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—breast cancer	7.53e-06	7.86e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC2A5—breast cancer	7.42e-06	7.74e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLCO1B1—breast cancer	7.42e-06	7.74e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CA—breast cancer	7.37e-06	7.7e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CG—breast cancer	7.31e-06	7.64e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNG—breast cancer	7.28e-06	7.6e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOA2—breast cancer	7.25e-06	7.57e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MDM2—breast cancer	7.24e-06	7.56e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RAF1—breast cancer	7.21e-06	7.53e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RELA—breast cancer	7.18e-06	7.5e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—APRT—breast cancer	7.16e-06	7.48e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERBB2—breast cancer	7.14e-06	7.45e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MTOR—breast cancer	7.04e-06	7.35e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CB—breast cancer	7.04e-06	7.35e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—FASN—breast cancer	7.03e-06	7.34e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD4—breast cancer	7.03e-06	7.34e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—breast cancer	7e-06	7.31e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HRAS—breast cancer	6.82e-06	7.12e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ESRRA—breast cancer	6.73e-06	7.03e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ANGPTL4—breast cancer	6.73e-06	7.03e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1B—breast cancer	6.61e-06	6.9e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6—breast cancer	6.53e-06	6.81e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL1B—breast cancer	6.49e-06	6.78e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL2—breast cancer	6.47e-06	6.75e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CD—breast cancer	6.43e-06	6.71e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—breast cancer	6.4e-06	6.69e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GPI—breast cancer	6.38e-06	6.67e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HADHB—breast cancer	6.38e-06	6.67e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALB—breast cancer	6.35e-06	6.63e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—JUN—breast cancer	6.29e-06	6.57e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTNNB1—breast cancer	6.24e-06	6.52e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOA1—breast cancer	6.11e-06	6.38e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1A—breast cancer	6.1e-06	6.37e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALDH7A1—breast cancer	6.09e-06	6.36e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALDH1A1—breast cancer	6.09e-06	6.36e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTEN—breast cancer	6.08e-06	6.35e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NOS3—breast cancer	6.07e-06	6.34e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—AKT1—breast cancer	6.02e-06	6.29e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—breast cancer	6.02e-06	6.29e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAPK8—breast cancer	5.95e-06	6.22e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ADSL—breast cancer	5.84e-06	6.1e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NME1—breast cancer	5.84e-06	6.1e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PHGDH—breast cancer	5.84e-06	6.1e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—UMPS—breast cancer	5.84e-06	6.1e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—FHL2—breast cancer	5.84e-06	6.1e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—BRIP1—breast cancer	5.73e-06	5.98e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HPSE—breast cancer	5.73e-06	5.98e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—LDHB—breast cancer	5.73e-06	5.98e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—SRC—breast cancer	5.64e-06	5.89e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CB—breast cancer	5.6e-06	5.85e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS2—breast cancer	5.55e-06	5.8e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—STAT3—breast cancer	5.44e-06	5.68e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA3—breast cancer	5.43e-06	5.67e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HMMR—breast cancer	5.43e-06	5.67e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCC1—breast cancer	5.43e-06	5.67e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPARGC1B—breast cancer	5.26e-06	5.49e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAPK3—breast cancer	5.2e-06	5.43e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—breast cancer	5.12e-06	5.34e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—breast cancer	5.12e-06	5.34e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CA9—breast cancer	4.96e-06	5.18e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA4—breast cancer	4.96e-06	5.18e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGFR—breast cancer	4.95e-06	5.16e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—breast cancer	4.9e-06	5.12e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—breast cancer	4.85e-06	5.07e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTEN—breast cancer	4.84e-06	5.06e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GPX2—breast cancer	4.84e-06	5.05e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA2—breast cancer	4.84e-06	5.05e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SULT1A1—breast cancer	4.78e-06	4.99e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GPX4—breast cancer	4.78e-06	4.99e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—breast cancer	4.67e-06	4.88e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—IDH1—breast cancer	4.67e-06	4.87e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTA1—breast cancer	4.67e-06	4.87e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NAT2—breast cancer	4.62e-06	4.82e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CA—breast cancer	4.29e-06	4.48e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—breast cancer	4.17e-06	4.36e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—DPYD—breast cancer	4.05e-06	4.23e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MED12—breast cancer	4.05e-06	4.23e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALDOA—breast cancer	3.98e-06	4.16e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HRAS—breast cancer	3.97e-06	4.15e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOA3—breast cancer	3.87e-06	4.04e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC2A2—breast cancer	3.84e-06	4.01e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6—breast cancer	3.8e-06	3.97e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	3.8e-06	3.97e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCG2—breast cancer	3.76e-06	3.93e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CPT1A—breast cancer	3.76e-06	3.93e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MTR—breast cancer	3.76e-06	3.93e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HPGDS—breast cancer	3.69e-06	3.85e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HBA1—breast cancer	3.67e-06	3.83e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTT1—breast cancer	3.58e-06	3.74e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ACHE—breast cancer	3.58e-06	3.74e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—AKT1—breast cancer	3.51e-06	3.66e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CA—breast cancer	3.42e-06	3.57e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP17A1—breast cancer	3.39e-06	3.54e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ENO1—breast cancer	3.35e-06	3.5e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS1—breast cancer	3.35e-06	3.5e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	3.34e-06	3.49e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ALB—breast cancer	3.3e-06	3.44e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2D6—breast cancer	3.29e-06	3.43e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOA2—breast cancer	3.23e-06	3.37e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—FASN—breast cancer	3.13e-06	3.27e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—BCHE—breast cancer	3.12e-06	3.26e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC5A5—breast cancer	3.08e-06	3.22e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NQO1—breast cancer	2.97e-06	3.11e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC2A1—breast cancer	2.97e-06	3.11e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	2.91e-06	3.04e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP3A4—breast cancer	2.9e-06	3.03e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	2.89e-06	3.01e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP1B1—breast cancer	2.85e-06	2.98e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HSP90AA1—breast cancer	2.8e-06	2.92e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKT1—breast cancer	2.79e-06	2.91e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOA1—breast cancer	2.72e-06	2.84e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—STK11—breast cancer	2.68e-06	2.8e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP19A1—breast cancer	2.68e-06	2.8e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	2.52e-06	2.63e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—COMT—breast cancer	2.49e-06	2.6e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTP1—breast cancer	2.48e-06	2.59e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HMOX1—breast cancer	2.45e-06	2.55e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ITPR1—breast cancer	2.44e-06	2.55e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCB1—breast cancer	2.35e-06	2.45e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TYMS—breast cancer	2.31e-06	2.41e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PLA2G4A—breast cancer	2.28e-06	2.38e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTM1—breast cancer	2.28e-06	2.38e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOR1—breast cancer	2.28e-06	2.38e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GPX1—breast cancer	2.18e-06	2.28e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP1A1—breast cancer	2.16e-06	2.26e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ERCC2—breast cancer	2.14e-06	2.24e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MTHFR—breast cancer	2.01e-06	2.1e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CAV1—breast cancer	1.86e-06	1.94e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.78e-06	1.85e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CG—breast cancer	1.69e-06	1.77e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CD—breast cancer	1.49e-06	1.55e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALB—breast cancer	1.47e-06	1.53e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NOS3—breast cancer	1.41e-06	1.47e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CB—breast cancer	1.3e-06	1.35e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS2—breast cancer	1.29e-06	1.34e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTEN—breast cancer	1.12e-06	1.17e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CA—breast cancer	7.91e-07	8.26e-06	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKT1—breast cancer	6.46e-07	6.74e-06	CbGpPWpGaD
